Vigil Neuroscience (VIGL) Competitors

Janux Therapeutics (NASDAQ:JANX) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.

Do insiders and institutionals hold more shares of JANX or VIGL?

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by company insiders. Comparatively, 18.0% of Vigil Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to JANX or VIGL?

In the previous week, Janux Therapeutics had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 10 mentions for Janux Therapeutics and 9 mentions for Vigil Neuroscience. Janux Therapeutics' average media sentiment score of 1.13 beat Vigil Neuroscience's score of 1.04 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vigil Neuroscience	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate JANX or VIGL?

Janux Therapeutics currently has a consensus target price of $95.25, indicating a potential upside of 279.48%. Vigil Neuroscience has a consensus target price of $10.80, indicating a potential upside of 37.23%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Janux Therapeutics is more favorable than Vigil Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.09
Vigil Neuroscience	0 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk and volatility, JANX or VIGL?

Janux Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.43, suggesting that its stock price is 243% more volatile than the S&P 500.

Is JANX or VIGL more profitable?

Vigil Neuroscience has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Vigil Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	-463.91%	-10.47%	-9.86%
Vigil Neuroscience	N/A	-83.89%	-65.34%

Which has preferable valuation and earnings, JANX or VIGL?

Janux Therapeutics has higher revenue and earnings than Vigil Neuroscience. Janux Therapeutics is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$9.34M	159.09	-$58.29M	-$1.36	-18.46
Vigil Neuroscience	N/A	N/A	-$82.64M	-$2.05	-3.84

Does the MarketBeat Community favor JANX or VIGL?

Janux Therapeutics received 9 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. Likewise, 70.97% of users gave Janux Therapeutics an outperform vote while only 67.31% of users gave Vigil Neuroscience an outperform vote.

Company	Underperform	Outperform
Janux Therapeutics	Outperform Votes 44 70.97%	Underperform Votes 18 29.03%
Vigil Neuroscience	Outperform Votes 35 67.31%	Underperform Votes 17 32.69%

Summary

Janux Therapeutics beats Vigil Neuroscience on 13 of the 18 factors compared between the two stocks.